Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1924 1
1928 1
1931 1
1932 1
1951 1
1952 1
1972 2
1975 9
1976 15
1977 13
1978 8
1979 17
1980 15
1981 20
1982 19
1983 22
1984 28
1985 30
1986 32
1987 20
1988 41
1989 46
1990 42
1991 54
1992 51
1993 74
1994 93
1995 113
1996 101
1997 128
1998 131
1999 124
2000 163
2001 152
2002 155
2003 160
2004 188
2005 189
2006 193
2007 210
2008 223
2009 240
2010 294
2011 322
2012 363
2013 413
2014 414
2015 426
2016 485
2017 513
2018 619
2019 793
2020 553
Text availability
Article attribute
Article type
Publication date

Search Results

7,501 results
Results by year
Filters applied: . Clear all
Page 1
Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age.
Crippa JA, Guimarães FS, Campos AC, Zuardi AW. Crippa JA, et al. Front Immunol. 2018 Sep 21;9:2009. doi: 10.3389/fimmu.2018.02009. eCollection 2018. Front Immunol. 2018. PMID: 30298064 Free PMC article. Review.
Background: Among the many cannabinoids in the cannabis plant, cannabidiol (CBD) is a compound that does not produce the typical subjective effects of marijuana. ...Methods: A non-systematic search was performed for studies dealing with therapeutic applications of CBD …
Background: Among the many cannabinoids in the cannabis plant, cannabidiol (CBD) is a compound that does not produce the typical subj …
Cannabidiol (CBD) and its analogs: a review of their effects on inflammation.
Burstein S. Burstein S. Bioorg Med Chem. 2015 Apr 1;23(7):1377-85. doi: 10.1016/j.bmc.2015.01.059. Epub 2015 Feb 7. Bioorg Med Chem. 2015. PMID: 25703248 Review.
This was no doubt due to the belief that activity meant psychoactivity that was shown by THC and not by CBD. In retrospect this must be seen as unfortunate since a number of actions of CBD with potential therapeutic benefit were downplayed for many years. ...Topics …
This was no doubt due to the belief that activity meant psychoactivity that was shown by THC and not by CBD. In retrospect this must …
In vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer's Disease.
Watt G, Karl T. Watt G, et al. Front Pharmacol. 2017 Feb 3;8:20. doi: 10.3389/fphar.2017.00020. eCollection 2017. Front Pharmacol. 2017. PMID: 28217094 Free PMC article. Review.
Importantly, CBD also reverses and prevents the development of cognitive deficits in AD rodent models. Interestingly, combination therapies of CBD and Δ(9)-tetrahydrocannabinol (THC), the main active ingredient of cannabis sativa, show that CBD can antagonize …
Importantly, CBD also reverses and prevents the development of cognitive deficits in AD rodent models. Interestingly, combination the …
Cannabidiol (CBD) use in psychiatric disorders: A systematic review.
Bonaccorso S, Ricciardi A, Zangani C, Chiappini S, Schifano F. Bonaccorso S, et al. Neurotoxicology. 2019 Sep;74:282-298. doi: 10.1016/j.neuro.2019.08.002. Epub 2019 Aug 11. Neurotoxicology. 2019. PMID: 31412258 Review.
Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) are the most represented phytocannabinoids in Cannabis sativa plants. However, CBD may present with a different activity compared with the psychotomimetic THC. Most typically, CBD is reported to be used in s …
Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) are the most represented phytocannabinoids in Cannabis sativa plants. However, …
Pharmacokinetic and behavioural profile of THC, CBD, and THC+CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC.
Hložek T, Uttl L, Kadeřábek L, Balíková M, Lhotková E, Horsley RR, Nováková P, Šíchová K, Štefková K, Tylš F, Kuchař M, Páleníček T. Hložek T, et al. Eur Neuropsychopharmacol. 2017 Dec;27(12):1223-1237. doi: 10.1016/j.euroneuro.2017.10.037. Epub 2017 Nov 10. Eur Neuropsychopharmacol. 2017. PMID: 29129557
THC, CBD and THC+CBD. Concentrations of THC, its metabolites 11-OH-THC and THC-COOH, and CBD in serum and brain were determined over 24h, locomotor activity (open field) and sensorimotor gating (prepulse inhibition, PPI) were also evaluated. ...In contrast, o …
THC, CBD and THC+CBD. Concentrations of THC, its metabolites 11-OH-THC and THC-COOH, and CBD in serum and brain were de …
The Role of Cannabidiol (CBD) in Chronic Pain Management: An Assessment of Current Evidence.
Boyaji S, Merkow J, Elman RNM, Kaye AD, Yong RJ, Urman RD. Boyaji S, et al. Curr Pain Headache Rep. 2020 Jan 24;24(2):4. doi: 10.1007/s11916-020-0835-4. Curr Pain Headache Rep. 2020. PMID: 31980957 Review.
RECENT FINDINGS: By examining recent literature, we investigated the use of CBD and its potential role in pain management. Since there are currently no approved pharmaceutical products that contain CBD alone for the management of pain, this review focused on nabixim …
RECENT FINDINGS: By examining recent literature, we investigated the use of CBD and its potential role in pain management. Since ther …
Cannabidiol (CBD) Is a Novel Inhibitor for Exosome and Microvesicle (EMV) Release in Cancer.
Kosgodage US, Mould R, Henley AB, Nunn AV, Guy GW, Thomas EL, Inal JM, Bell JD, Lange S. Kosgodage US, et al. Front Pharmacol. 2018 Aug 13;9:889. doi: 10.3389/fphar.2018.00889. eCollection 2018. Front Pharmacol. 2018. PMID: 30150937 Free PMC article.
CBD significantly reduced exosome release in all three cancer cell lines, and also significantly, albeit more variably, inhibited microvesicle release. ...We suggest that the known anti-cancer effects of CBD may partly be due to the regulatory effects on EMV biogene …
CBD significantly reduced exosome release in all three cancer cell lines, and also significantly, albeit more variably, inhibited mic …
Potential Clinical Benefits of CBD-Rich Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy: Observational Data Meta-analysis.
Pamplona FA, da Silva LR, Coan AC. Pamplona FA, et al. Front Neurol. 2018 Sep 12;9:759. doi: 10.3389/fneur.2018.00759. eCollection 2018. Front Neurol. 2018. PMID: 30258398 Free PMC article.
Patients treated with CBD-rich extracts reported lower average dose (6.0 mg/kg/day) [DOSAGE ERROR CORRECTED] than those using purified CBD (25.3 mg/kg/day). ...CBD-rich extracts seem to present a better therapeutic profile than purified CBD, at least i …
Patients treated with CBD-rich extracts reported lower average dose (6.0 mg/kg/day) [DOSAGE ERROR CORRECTED] than those using purifie …
Cannabidiol (CBD) for Treatment of Neurofibromatosis-related Pain and Concomitant Mood Disorder: A Case Report.
Hegazy O, Platnick H. Hegazy O, et al. Cureus. 2019 Dec 6;11(12):e6312. doi: 10.7759/cureus.6312. Cureus. 2019. PMID: 31938604 Free PMC article.
Cannabidiol (CBD) is the major non-psychotropic component of cannabis. CBD has shown anti-inflammatory and analgesic properties, as well as having mood stabilizer and anxiolytic effects. In this report, we present the use of cannabidiol (CBD) for the manageme …
Cannabidiol (CBD) is the major non-psychotropic component of cannabis. CBD has shown anti-inflammatory and analgesic propertie …
Potency Assessment of CBD Oils by Their Effects on Cell Signaling Pathways.
Urasaki Y, Beaumont C, Workman M, Talbot JN, Hill DK, Le TT. Urasaki Y, et al. Nutrients. 2020 Jan 30;12(2):357. doi: 10.3390/nu12020357. Nutrients. 2020. PMID: 32019055 Free PMC article.
Isolated CBD was cytotoxic, with an effective concentration (EC(50)) of 40 µM. In contrast, the CBD oils had no effect on cell viability at CBD concentrations exceeding 1.2 mM. ...The remaining CBD oils, which were adulterated, and isolated CBD …
Isolated CBD was cytotoxic, with an effective concentration (EC(50)) of 40 µM. In contrast, the CBD oils had no effect on cell …
7,501 results
Jump to page
Feedback